Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Weapon for Fighting Antibiotic Drug Resistance

12.08.2003


The most important antibiotics in general use today are the b-lactam family of products, but the medical community faces a serious problem with these antibiotics: the increasing development of drug resistance. The resistance is caused by hydrolysis of the b-lactam by a bacterial lactamase enzyme, but fortunately it can often be overcome by the use of a serine b-lactamase inhibitor in combination with the drug. This approach is successfully used already, for example clavulanic acid is used in combination with amoxycillin in Augmentin.



Unfortunately, various b-lactam drugs are also inactivated by metallo-b-lactamases, which cannot be overcome by the current range of serine b-lactamase inhibitors. Until recently, there have been no metallo-b-lactamase inhibitors of any kind to protect the drugs from this type of resistance.

Researchers at Oxford University’s Department of Chemistry now believe they have found a solution to this problem. They have discovered a new class of inhibitors of Class B bacterial lactamases, which are responsible for the hydrolysis of many antibiotics and hence drug resistance in those bacteria.


The researchers identified a number of potentially useful inhibitor compounds, which are mainly perfluoroalkyl derivatives of a-amino acids or a peptide, made by either conventional routes or by a novel method involving oxazolidinone formation, silylation and desilylation with ring cleavage. Assays for inhibition were carried out using the published procedures of Walter et al to yield inhibition constants, and kinetic data is also available for certain compounds.

The new metallo-b-lactamase inhibitors provide an attractive alternative approach to enhancing antibiotic performance and overcoming antibiotic resistance in bacteria.

Isis Innovation, Oxford’s technology transfer company, holds a granted patent on this novel technology and welcomes contact from companies interested in commercially developing this technology for the drug industry.

Jennifer Johnson | alfa
Further information:
http://www.isis-innovation.com/licensing/29.html

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>